Skip to main content

ImmunityBio, Inc. (IBRX) Stock

ImmunityBio, Inc. Stock Details, Movements and Public Alerts

Stock Details

ImmunityBio, Inc. (IBRX), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $9.41. Over the past 52 weeks, it has ranged between $1.95 and $12.43. This places the current price at 75.7% of its 52-week high and 382.6% above its 52-week low. Recent trading volume was recorded at 15,969. The 14-day Relative Strength Index (RSI) stands at 73.19, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $7.68 by 22.53%. Similarly, it is above its 200-day moving average of $5.40 by 74.26%. The MACD histogram is 0.26, indicating bullish momentum (MACD Line: 0.41, Signal Line: 0.15). There is currently 1 active alert set for IBRX by users.

52-Week Range

$12.43 - $1.95

-24.30% from high · +382.56% from low

Avg Daily Volume

13,370,021

20-day average

100-day avg: 21,390,279

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

157.33

EV/EBITDA

-43.32

EPS (TTM)

-$0.85

Price to Sales

70.13

Beta

0.08

Less volatile than market

Q:How is IBRX valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is IBRX's risk profile compared to the market?
With a beta of 0.08, ImmunityBio, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-157.88%

EBITDA

$-245,412,992

Return on Assets

-34.38%

Revenue Growth (YoY)

167.60%

Q:How profitable and efficient is IBRX's business model?
0 The operating margin of -157.88% reveals how efficiently the company runs its core business operations before interest and taxes.
Q:What are IBRX's recent growth trends?
ImmunityBio, Inc.'s revenue grew by 167.60% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$9.9B

Revenue (TTM)

$140.98M

Revenue/Share (TTM)

$0.15

Shares Outstanding

1.05B

Book Value/Share

-$0.83

Asset Type

EQUITY

Q:What is IBRX's market capitalization and position?
ImmunityBio, Inc. has a market capitalization of $9.9B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 1.05B shares outstanding, the company's ownership is widely distributed. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does IBRX's price compare to its book value?
ImmunityBio, Inc.'s book value per share is -$0.83, while the current stock price is $9.41, resulting in a price-to-book (P/B) ratio of -11.32. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$13.00

38.15% upside potential

Analyst Recommendations

Strong Buy

1

Buy

2

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for IBRX?
3 analysts cover IBRX with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $13.00 implies 38.2% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on IBRX?
Current analyst recommendations:1 Strong Buy, 2 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 6, 2026, 02:00 AM

Technical Indicators

RSI (14-day)

73.19

Overbought

50-Day Moving Average

$7.68

22.53% above MA-50

200-Day Moving Average

$5.40

74.26% above MA-200

MACD Line

0.41

MACD Signal

0.15

MACD Histogram

0.26

Bullish

Q:What does IBRX's RSI value tell investors?
The RSI (Relative Strength Index) for IBRX is currently 73.19, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret IBRX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.41 above the signal line at 0.15, with histogram at 0.26. This bullish crossover suggests upward momentum is building. The 50-day MA ($7.68) is above the 200-day MA ($5.40), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Jul 6, 2026, 01:12 AM

Active Alerts

Alert Condition
Price rises above
Threshold
$12.43
Created
Mar 1, 2026, 04:02 AM

Stay Ahead of the Market with ImmunityBio, Inc. Alerts

Set up price alerts for ImmunityBio, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.